Pub. Date : 2012 Feb
PMID : 22089930
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | RESULTS: The ABL-inhibitors imatinib and nilotinib activate MAPKs in CD34+ chronic myelogenous leukemia progenitor cells, whereas treatment with the SRC/ABL-inhibitor dasatinib does not affect MAPK-activation at clinically relevant concentrations. | Dasatinib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |